The landscape of therapeutics for Niemann-Pick Disease Type C (NPC) is a dynamic one, with significant strides being made in research. Several promising therapeutic methods are currently undergoing clinical trials, offering encouragement for sufferers living with this rare and worsening brain-related disorder. A blend of drug-driven therapies and